November 17, 2016 - By Dolores Ford · 0 Comments
The stock of Transgenomic Incorporated (NASDAQ:TBIO) registered an increase of 15.26% in short interest. TBIO’s total short interest was 182,800 shares in November as published by FINRA. Its up 15.26% from 158,600 shares, reported previously. With 140,700 shares average volume, it will take short sellers 1 days to cover their TBIO’s short positions. The short interest to Transgenomic Incorporated’s float is 2.21%. The stock closed at $0.182 during the last session. It is down 71.43% since April 15, 2016 and is downtrending. It has underperformed by 76.05% the S&P500.
Transgenomic, Inc. is a biotechnology company. The company has a market cap of $4.39 million. The Firm is engaged in advancing personalized medicine for the detection and treatment of cancer, and inherited diseases through its molecular technologies and clinical and research services. It currently has negative earnings. The Firm operates through its Laboratory Services segment.
Insitutional Activity: The institutional sentiment decreased to 0.63 in 2016 Q2. Its down 1.17, from 1.8 in 2016Q1. The ratio dropped, as 4 funds sold all Transgenomic Inc shares owned while 4 reduced positions. 2 funds bought stakes while 3 increased positions. They now own 8.44 million shares or 0.47% less from 8.48 million shares in 2016Q1.
Moreover, Advisory Networks Ltd Llc has 0% invested in Transgenomic Inc (NASDAQ:TBIO) for 1,974 shares. Ladenburg Thalmann Svcs accumulated 0% or 166 shares. Third Security Ltd Liability Com accumulated 0.22% or 7.55M shares. Fmr Ltd Liability accumulated 0% or 250,000 shares. Wells Fargo And Mn holds 12,913 shares or 0% of its portfolio. Vanguard Gru Inc, a Pennsylvania-based fund reported 120,899 shares. Geode Cap Ltd reported 13,347 shares or 0% of all its holdings. Northern Trust holds 11,055 shares or 0% of its portfolio. Manufacturers Life Insurance The accumulated 0% or 73 shares. The Minnesota-based White Pine Capital Ltd Com has invested 0.05% in Transgenomic Inc (NASDAQ:TBIO). Comml Bank Of America De, a North Carolina-based fund reported 502 shares. Kcg Hldgs, a New Jersey-based fund reported 18,817 shares. The Kansas-based Creative Planning has invested 0% in Transgenomic Inc (NASDAQ:TBIO). Blackrock Fund accumulated 0% or 2,797 shares. Goldman Sachs Gp has 0% invested in the company for 14,996 shares.
Transgenomic, Inc. (Transgenomic), incorporated on March 6, 1997, is a biotechnology company. The Firm is engaged in advancing personalized medicine for the detection and treatment of cancer, and inherited diseases through its molecular technologies and clinical and research services. The Firm operates through its Laboratory Services segment. The Firm is engaged in the provision of its Multiplexed ICE COLD-PCR (MX-ICP) product to the clinical market, enabling the use of blood and other bodily fluids for diagnosis, monitoring and treatment of cancer. MX-ICP amplifies the ability to detect genetic mutations by approximately 100 to 400 fold. MX-ICP is validated internally on sequencing platforms, including Sanger, Next Gen Sequencing and Digital polymerase chain reaction (PCR).
More notable recent Transgenomic Inc (NASDAQ:TBIO) news were published by: Businesswire.com which released: “Transgenomic Launches Most Comprehensive Genetic Test for Diagnosis of …” on July 14, 2015, also Businesswire.com with their article: “Transgenomic Launches New MX-ICP Panels for Liquid Biopsy Detection of RAS and …” published on January 19, 2016, Businesswire.com published: “Transgenomic Expands Board of Directors and Executive Team” on June 09, 2015. More interesting news about Transgenomic Inc (NASDAQ:TBIO) were released by: Businesswire.com and their article: “Transgenomic Study Data Shows 100% Concordance between ICE COLD-PCRâ„¢ (ICP …” published on May 16, 2016 as well as Businesswire.com‘s news article titled: “Transgenomic Launches EGFR CLIA Test That Accurately Detects Key Mutations in …” with publication date: May 29, 2015.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Dolores Ford